Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GSK2036874A (GSK)
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
GSK2036874A is an investigational hexavalent combination vaccine developed by GSK (GlaxoSmithKline) to provide active immunization against six major childhood diseases in a single injection. The vaccine targets diphtheria, tetanus, pertussis (whooping cough), hepatitis B, poliomyelitis, and invasive disease caused by Haemophilus influenzae type b (Hib). Its formulation includes diphtheria and tetanus toxoids, acellular pertussis antigens (pertussis toxoid, filamentous hemagglutinin, and pertactin), recombinant hepatitis B surface antigen (HBsAg), inactivated poliovirus (IPV) types 1, 2, and 3, and the Hib capsular polysaccharide (PRP) conjugated to a carrier protein. GSK2036874A was primarily evaluated in Phase 2 clinical trials (such as NCT00419770) to assess its safety and immunogenicity as a booster dose in toddlers, comparing its performance to established licensed vaccines like Zilbrix and Poliorix.
- Other names
- DTPa-HBV-IPV-Hib vaccineDTPa-HBV-IPV/Hib vaccine
02
Targets
HBsAg (Hepatitis B surface antigen)TT (Tetanus toxoid)
Beyond the preview
Go deeper on GSK2036874A (GSK).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GSK2036874A (GSK).